Professor Masakazu Toi
Professor Toi, Director of the Breast Cancer Unit at Kyoto University Hospital in Japan, provides his expert insight into key data presented at ASCO 2018 and what they may mean for optimizing clinical outcomes for patients with advanced breast cancer.
Key topics include:
TThe place of CDK4/6 inhibitors in relation to endocrine therapy in the treatment sequence for HR+/HER2- advanced breast cancer.
Whether the differing safety profiles of CDK4/6 inhibitors are important when making decisions regarding patient management.
The current challenges for conserving the quality of life of patients with HR+/HER2- advanced breast cancer, compared with managing disease progression.
Whether a broader choice of treatment options may be available in the near future for advanced breast cancer based on the wealth of early phase studies presented at ASCO 2018.
Specific data for advanced breast cancer that were of particular interest for Professor Toi at ASCO 2018, and any implications of these for the management of patients from a national and regional perspective in Japan.
Clinical Expert Video Series
Watch internationally renowned breast cancer clinicians discussing the latest data from the American Society of Clinical Oncology (ASCO) Annual Meeting 2018, Chicago, IL, US, June 1–5, and what they may mean for clinical practice.
Masakazu Toi graduated in 1982 from Hiroshima University School of Medicine with his Medical Doctorate and in 1988 with his PhD. He studied at the Institute of Molecular Medicine at Oxford University, UK, from 1990 to 1992. In 2007, Professor Toi was appointed Professor of Breast Surgery at the Graduate School of Medicine, Kyoto University, Japan, and Director of the Breast Cancer Unit, Kyoto University Hospital.
Professor Toi is passionate in his study of cancer, particularly breast cancer biology and treatment. He is keen on research that translates basic science into clinical study. He is involved in various innovative research projects on the development of new anticancer diagnostics and therapeutics including biomarkers, novel imaging and antibody treatment. He is engaged in clinical trials mainly associated with breast cancer treatment and research. He has a strong interest in the tumour microenvironment such as angiogenesis and stromal reactions.
Professor Toi belongs to various associations and is a member of several leading academic organizations. He serves as an editorial board member of multiple academic journals and has authored or co-authored over 300 articles.
Disclosures: Honoraria from Novartis, MSD, Takeda, AstraZeneca, Eisai, Genomic Health, Chugai Pharma, Taiho Pharmaceutical, Bayer, Eli Lilly, Daiichi Sankyo, Kyowa Hakko Kirin, C&C Research Laboratories, Yakult, Sanofi, Shimadzu and Pfizer. Consulting or advisory role for Daiichi Sankyo, Kyowa Hakko Kirin and Taiho Pharmaceutical. Speaker bureau for Pfizer and AstraZeneca.
ASCO 2018 Highlights